

## Press Release

For immediate release

### **Medix Biochemica Expands its Offering of Critical IVD Raw Materials to Premium Blockers and Stabilizers by Acquiring CANDOR Bioscience**

- Medix Biochemica acquires CANDOR Bioscience, a leading provider of premium immunoassay solutions, based in Wangen, Germany.
- The acquisition strengthens Medix Biochemica's portfolio in critical raw materials for in vitro diagnostics (IVD) and enhances its capability to support immunoassay developers across the world.
- Medix Biochemica's vision is to be the first-choice raw material partner for the IVD industry.

**22 January 2025, Espoo, Finland** – Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions. The acquisition both strengthens Medix Biochemica's range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development. Following the transaction, CANDOR Bioscience's high-quality operations will remain in Wangen im Allgäu, Germany.

CANDOR Bioscience, founded in 2004 by Dr Tobias Polifke and Dr Peter Rauch, is a German provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers and buffer solutions. By using CANDOR Bioscience's solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times.

"We are delighted to welcome CANDOR into the Medix Biochemica family. The partnership with CANDOR strengthens Medix Biochemica's ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team," says Steve Ferguson, CEO of Medix Biochemica.

Dr Tobias Polifke and Dr Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience, are excited about the partnership: "Joining forces with Medix Biochemica is an exciting milestone for CANDOR. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica's commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica's products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry".

[www.medixbiochemica.com](http://www.medixbiochemica.com)

**For more information, please contact:**

Steve Ferguson, CEO Medix Biochemica

Phone: +358 9 547 680 | Email: [steve.ferguson@medixbiochemica.com](mailto:steve.ferguson@medixbiochemica.com)

## Press Release

For immediate release

### About CANDOR Bioscience

CANDOR Bioscience GmbH specializes in the development and production of high-quality solutions for immunoassays. Its products, including stabilizers and blockers, are used globally to improve assay accuracy and reliability. Founded in 2004, CANDOR Bioscience has built a reputation for delivering superior quality products with consistent performance.

### About Medix Biochemica

Medix Biochemica is a market-leading, independent supplier of critical raw materials to the *in vitro* diagnostics (IVD) industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. The company's main owner is DevCo Partners, a long-term oriented active owner and development partner dedicated to building world-leading companies in selected niche markets.